In the early nineteenth century, curare became available to scientists who were quick to utilize it in animal experiments. Soon a vast array of drugs had been tested on paralysed and seemingly co-operative animals. Curare was self-limiting and the animals would recover spontaneously. In 1900, J. Pal, a physiologist in Vienna, was performing experiments on paralysed dogs to study the effects on peristalsis of physostigmine, a derivative of the Calabar bean 1 . On each occasion a marked increase in peristalsis occurred but the dog immediately started breathing spontaneously. Pal suspected that the drug was acting as an antidote to curare and conducted further experiments to confirm this. At the time this created more questions than it answered; it was known that physostigmine was a specific antagonist of atropine and that in large doses it caused muscle weakness and even paralysis. There was no ready explanation as to how all these facts were related. Pal mentioned that there were side-effects to the physostigmine and he stated, "Although atropine is particularly recommended for this, I think the addition of morphine is very useful". Given that the animals were probably awake throughout all these procedures, it is easy to see how morphine might have improved their physiological state.
In 1934, Dr Mary Walker at St Alfege's Hospital in Greenwich, realized that myasthenia gravis presented with similar symptoms to curare poisoning and injected one of her patients with physostigmine. The results were dramatic but short-lived. Dr Walker discussed this case extensively and published the case report but there was not a great deal of interest in this treatment 2, 3 . In June of that year she repeated the experiment with neostigmine (Prostigmin), an analogue of physostigmine that had just been released. The results were similar and eventually she managed to gain the attention of her colleagues. By the following year the profession was acknowledging a great breakthrough. Within months Hoffman-LaRoche, working with Dr Walker, had synthesised an oral preparation (Mestinon) which is still used today to treat myasthenic patients.
Thus, by the time curare was introduced into anaesthesia, there was a known antidote, largely used clinically as a parasympathetic stimulant for postoperative ileus and urinary retention, but also available for myasthenia gravis. Experience with curare in animals was extensive and it was well established that relaxation was selflimiting. But the existence of an antidote was clearly reassuring. When Harold Griffiths and Enid Johnson reported the first cases of relaxant anaesthesia in 1942 they stated:
"It has not been necessary to administer artificial respiration or stimulants in any of our cases. As our patients are all under gas anaesthesia, with means of resuscitation by oxygen immediately available, we do not fear this complication. Since prostigmine is used as an antidote to curare, an ampule of this drug should always be available." 4 Over the next decade, neostigmine became the preferred antidote but its muscarinic side-effects were problematic and may have led to some fatalities. As a result, a safer reversal agent was sought. Tensilon (3 hydroxy-phenyl dimethyl ethyl ammonium bromide, or edrophonium) was selected from a group of compounds as the one possessing the greatest anticholinergic activity and the least muscarinic effect. A number of clinical trials were conducted but it was soon clear that its duration of action was too short. A. R. Hunter of the Manchester Royal Infirmary concluded after his trial, that "Tensilon, though free from the more serious muscarinic actions of neostigmine, is not as reliable an antidote to the muscle paralysing action of d-tubocurarine" 5 .
Pyridostigmine (Mestinon) was also tried as a reversal agent. Some found it to be satisfactory and to have fewer side-effects but overall it was slow acting and unpredictable. Neostigmine, therefore, remained the drug of choice for reversal of relaxant anaes-thesia. There were regional differences in its use. In Eng land, Thomas Cecil Gray perfected and publicized his preferred technique of light anaesthesia with controlled hyperventilationthe so-called "Liverpool technique". This technique was swiftly adopted in the United Kingdom with regular use of neostigmine and atropine at the conclusion of the anaesthetic.
In America a different picture developed. American anaesthetists continued with small doses of relaxants and spontaneously breathing patients. In 1954, Beecher and Todd published a report into curare anaesthesia which concluded that the death rate from surgery had risen six-fold in the years between 1948 and 1952, following the introduction of curare. In retrospect it is clear that the problem lay in the way curare was utilized. About 90% of these anaesthetics were given by non-specialist anaesthetists, often nurse practitioners who were not trained in artificial respiration. The use of curare declined in America over the next few years as a result of these findings.
Other problems surfaced in Britain where the use of neostigmine was extensive. In 1956, Andrew Hunter, a British anaesthetist, described six patients with neostigmine resistance who subsequently died 6 . These patients all had operations for prolonged bowel obstruction, were unable to be reversed with neostigmine at the end of the procedure and died of cardiac failure. The relationship of this problem to acid/base disturbances was realized some years later. Other relationships became apparent and in 1976, Ronald Miller reviewed all the factors that influence satisfactory reversal of relaxants such as temperature, electrolyte imbalance, some antibiotics and other drugs 6 .
There have been experiments with other reversal agents. 4-aminopyridine, a potassium channel blocker, was used in the 1980s 7 . It is effective but has extensive side-effects. It does have therapeutic uses in neurological conditions such as myasthenia gravis, Eaton Lambert syndrome, multiple sclerosis and epilepsy.
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